In 2019, Professor Vladyslav Povoroznyuk and the team of co-authors were awarded a diploma by the Presidium of the National Academy of Medical Sciences of Ukraine and D. F. Chebotarev prize for a collection of studies entitled “Mechanisms of development, diagnostics, prevention and treatment of bone-muscular diseases in the elderly people”.
Osteoporosis is one of the key healthcare problems across the world. According to the international experts, this condition has become a virtual epidemic. The principal feature distinguishing osteoporosis from the other locomotor apparatus diseases is an almost entire absence of clinical manifestations up to the fracture occurring. Only one in three vertebral fractures is clinically detected (Briggs A.M., 2007; Genant H.K., 2002; Поворознюк В.В., 2009).
Taking into account a significant medico-social importance of osteoporosis, it is very important to evaluate the bone tissue at the early stages.
«Dual X- Ray absorptiometry is considered a ‘gold standard’ of bone mineral assessment.
According to the International Society for Clinical Densitometry’s Recommendations of 2015 (The International Society For Clinical Densitometry, 2015), the following groups of patients should be referred for the bone mineral density assessment:
- Women of 65 years and over.
- Postmenopausal women younger than 65 years with the following risk factors: low body mass, previous fractures, medications affecting the bone tissue, conditions associated with bone loss.
- Perimenopausal women with clinical risk factors: low body mass, previous fractures, medications affecting the bone tissue.
- Men of 70 years and over.
- Men younger than 70 years with the following risk factors: low body mass, previous fractures, medications affecting the bone tissue, conditions associated with bone loss.
- Patients with previous fragility fractures.
- Patients with conditions associated with bone loss.
- Patients on medications affecting the bone tissue.
You’re invited to the Ukrainian Scientific-Medical Center of Osteoporosis Problems for a densitometric assessment (Link to Book an Appointment) with Hologic (Discovery WI, USA) и Prodigy (GEHC Lunar WI, USA).
RECORD ON RECEPTION
2019 EUROPEAN RECOMMENDATIONS ON SARCOPENIA DIAGNOSTICS (EWGSOP, 2019)
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
According to the revised European Working Group on Sarcopenia in Older People (EWGSOP) consensus of 2019, sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality.
In September 2016, the diagnosis of sarcopenia was officially included in the supplemented 10th international classification of diseases under the code M 62.84
Diagnostic criteria (EWGSOP, 2019):
- Low muscle strength
- Low muscle quantity or quality
- Low physical performance
Sarcopenia stages (EWGSOP, 2019)
Stages |
Skeletal muscle strength |
Skeletal muscle mass/quality |
|
Skeletal muscle performance |
Probable sarcopenia |
↓ |
|
|
|
Sarcopenia |
↓ |
↓ |
or |
↓ |
Severe sarcopenia |
↓ |
↓ |
|
↓ |
Sarcopenia “cut-off” points (EWGSOP, 2019)
Diagnostic test |
Men |
Women |
Skeletal muscle strength “cut-off” points |
||
Grip strength, kg (hand dynamometrics) |
< 27 |
< 16 |
Chair stand |
> 15 sec / 5 times |
not available |
Skeletal muscle mass “cut-off” points |
||
Appendicular Lean Mass (ALM), kg |
< 20 |
< 15 |
Appendicular Lean Mass index , kg/m2 |
< 7.0 |
< 6.0 |
Skeletal muscle performance “cut-off” points |
||
Gait speed, m/sec |
≤ 8 |
not available |
SPPB test |
≤ 8 |
|
“3-m walk” test, sec |
≥20 |
|
“400-m walk” test, sec |
Failure or performance ≥ 6 minutes |
2019 EWGSOP’s updated diagnostic («Find-Asess-Confirm-Severity» (F-A-C-S)) algorithm targeted at sarcopenia
SARC-F: sarcopenia diagnostic questionnaire
Interpretation of findings: total value of over 4 points indicates a high probability of sarcopenia and its adverse consequences in an examined patient.
N.I. Dzerovych
2019 European recommendations on sarcopenia diagnosis
http://osteoporos.com.ua/uk/ukrainska-asociacija-osteoporozu/publikatsii/zhurnal2
In June 4, 2016 Prof. Vladyslav Volodymyrovych Povoroznyuk, President of the Ukrainian Association of Osteoporosis was awarded at the annual summit of the International Society for Clinical Densitometry (ISCD) held in Galway, Ireland, for his leadership and significant achievements in clinical densitometry with John P. Bilezikian ISCD Global Leadership Award. (John P. Bilezikian ISCD Global Leadership Award).
In April 2-5, 2014 in Seville, Spain, the World Congress of Osteoporosis, Osteoarthritis, and Bone and Joint Diseases was held under the auspices of the (International osteoporosis Foundation (IOF)) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
In 2014, the IOF’s Committee established a Medal for the active participation in the Committee of National Societies (CNS)’s activities and spreading the IOF’s mission.
Prof. Vladyslav Volodymyrovych Povoroznyuk, President of the Ukrainian Association of Osteoporosis, was chosen as the first awardee.
J. Stenmark, Managing Director of the International osteoporosis Foundation (IOF); Prof. Vladyslav Volodymyrovych Povoroznyuk, President of the Ukrainian Association of Osteoporosis; J. Reginster, President of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).